Theriva Biologics Inc

For the period ended Dec 31, 2024. Filed Mar 6, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 6, 2025

TOVX$0.17-0.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Page
	PART I.	3

Item 1.	Business	6

Item 1A.	Risk Factors	35

Item 1B.	Unresolved Staff Comments	65

Item 1C.	Cybersecurity	65

Item 2.	Properties	66

Item 3.	Legal Proceedings	66

Item 4.	Mine Safety Disclosures	66

	PART II.	67

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	67

Item 6.	[Reserved]	67

Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	68

Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	77

Item 8.	Financial Statements and Supplementary Data	78

Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	118

Item 9A.	Controls and Procedures	118

Item 9B.	Other Information	119

Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	120

	PART III.	121

Item 10.	Directors, Executive Officers and Corporate Governance	121

Item 11.	Executive Compensation	124

Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	133

Item 13.	Certain Relationships and Related Transactions, and Director Independence	134

Item 14.	Principal Accountant Fees and Services	135

	PART IV.	136
Item 15.	Exhibits and Financial Statement Schedules	136

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents